RU2001130883A - Новые полиморфные формы антидиабетического средства, способ их получения и содержащие их фармацевтические композиции - Google Patents
Новые полиморфные формы антидиабетического средства, способ их получения и содержащие их фармацевтические композицииInfo
- Publication number
- RU2001130883A RU2001130883A RU2001130883/04A RU2001130883A RU2001130883A RU 2001130883 A RU2001130883 A RU 2001130883A RU 2001130883/04 A RU2001130883/04 A RU 2001130883/04A RU 2001130883 A RU2001130883 A RU 2001130883A RU 2001130883 A RU2001130883 A RU 2001130883A
- Authority
- RU
- Russia
- Prior art keywords
- ethoxy
- phenyl
- phenoxazin
- arginine salt
- ethoxypropanoic acid
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims 22
- 238000004519 manufacturing process Methods 0.000 title claims 4
- 239000003472 antidiabetic agent Substances 0.000 title 1
- 229940125708 antidiabetic agent Drugs 0.000 title 1
- LCBJEJLDEGRRPF-OMTJCYKGSA-N (2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid;(2s)-2-ethoxy-3-[4-(2-phenoxazin-10-ylethoxy)phenyl]propanoic acid Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N.C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCCN1C2=CC=CC=C2OC2=CC=CC=C21 LCBJEJLDEGRRPF-OMTJCYKGSA-N 0.000 claims 38
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 35
- 238000000034 method Methods 0.000 claims 35
- WMUIIGVAWPWQAW-DEOSSOPVSA-N (2s)-2-ethoxy-3-{4-[2-(10h-phenoxazin-10-yl)ethoxy]phenyl}propanoic acid Chemical compound C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCCN1C2=CC=CC=C2OC2=CC=CC=C21 WMUIIGVAWPWQAW-DEOSSOPVSA-N 0.000 claims 32
- 239000000203 mixture Substances 0.000 claims 26
- 125000002059 L-arginyl group Chemical class O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 claims 25
- 238000001757 thermogravimetry curve Methods 0.000 claims 25
- 238000003756 stirring Methods 0.000 claims 23
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 23
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 20
- 239000002244 precipitate Substances 0.000 claims 20
- 208000035475 disorder Diseases 0.000 claims 19
- 208000002705 Glucose Intolerance Diseases 0.000 claims 16
- 206010020772 Hypertension Diseases 0.000 claims 16
- 208000008589 Obesity Diseases 0.000 claims 16
- 208000001132 Osteoporosis Diseases 0.000 claims 16
- 201000010099 disease Diseases 0.000 claims 16
- 208000017169 kidney disease Diseases 0.000 claims 16
- 235000020824 obesity Nutrition 0.000 claims 16
- 206010022489 Insulin Resistance Diseases 0.000 claims 15
- 238000001035 drying Methods 0.000 claims 15
- 238000001914 filtration Methods 0.000 claims 15
- -1 or kolesiptol Chemical compound 0.000 claims 15
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 15
- 239000000243 solution Substances 0.000 claims 14
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 13
- 238000011282 treatment Methods 0.000 claims 13
- 238000010521 absorption reaction Methods 0.000 claims 12
- 238000000634 powder X-ray diffraction Methods 0.000 claims 12
- 230000005855 radiation Effects 0.000 claims 12
- 208000011580 syndromic disease Diseases 0.000 claims 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 11
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims 11
- 229930064664 L-arginine Natural products 0.000 claims 11
- 235000014852 L-arginine Nutrition 0.000 claims 11
- 230000015572 biosynthetic process Effects 0.000 claims 11
- 238000004090 dissolution Methods 0.000 claims 11
- 239000011541 reaction mixture Substances 0.000 claims 11
- 238000003786 synthesis reaction Methods 0.000 claims 11
- 229920001268 Cholestyramine Polymers 0.000 claims 10
- 229940125753 fibrate Drugs 0.000 claims 10
- 229960003512 nicotinic acid Drugs 0.000 claims 10
- 235000001968 nicotinic acid Nutrition 0.000 claims 10
- 239000011664 nicotinic acid Substances 0.000 claims 10
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 claims 10
- 229960003912 probucol Drugs 0.000 claims 10
- 239000007787 solid Substances 0.000 claims 10
- 239000000126 substance Substances 0.000 claims 10
- 206010003210 Arteriosclerosis Diseases 0.000 claims 8
- 201000001320 Atherosclerosis Diseases 0.000 claims 8
- 208000024172 Cardiovascular disease Diseases 0.000 claims 8
- 206010012289 Dementia Diseases 0.000 claims 8
- 208000002249 Diabetes Complications Diseases 0.000 claims 8
- 206010012655 Diabetic complications Diseases 0.000 claims 8
- 208000032928 Dyslipidaemia Diseases 0.000 claims 8
- 206010018364 Glomerulonephritis Diseases 0.000 claims 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 8
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 8
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 8
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 8
- 108010028554 LDL Cholesterol Proteins 0.000 claims 8
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 8
- 206010068871 Myotonic dystrophy Diseases 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 8
- 206010033645 Pancreatitis Diseases 0.000 claims 8
- 201000004681 Psoriasis Diseases 0.000 claims 8
- 208000017442 Retinal disease Diseases 0.000 claims 8
- 206010038923 Retinopathy Diseases 0.000 claims 8
- 108010069201 VLDL Cholesterol Proteins 0.000 claims 8
- 206010048214 Xanthoma Diseases 0.000 claims 8
- 206010048215 Xanthomatosis Diseases 0.000 claims 8
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 8
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 230000020411 cell activation Effects 0.000 claims 8
- 230000003920 cognitive function Effects 0.000 claims 8
- 208000029078 coronary artery disease Diseases 0.000 claims 8
- 210000002889 endothelial cell Anatomy 0.000 claims 8
- 235000021588 free fatty acids Nutrition 0.000 claims 8
- 206010061989 glomerulosclerosis Diseases 0.000 claims 8
- 239000008103 glucose Substances 0.000 claims 8
- 201000001421 hyperglycemia Diseases 0.000 claims 8
- 230000001631 hypertensive effect Effects 0.000 claims 8
- 201000009925 nephrosclerosis Diseases 0.000 claims 8
- 239000003960 organic solvent Substances 0.000 claims 8
- 201000009104 prediabetes syndrome Diseases 0.000 claims 8
- 150000003626 triacylglycerols Chemical class 0.000 claims 8
- 102000016267 Leptin Human genes 0.000 claims 7
- 108010092277 Leptin Proteins 0.000 claims 7
- 239000002253 acid Substances 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 7
- 239000003112 inhibitor Substances 0.000 claims 7
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims 7
- 229940039781 leptin Drugs 0.000 claims 7
- 230000008289 pathophysiological mechanism Effects 0.000 claims 7
- 230000002265 prevention Effects 0.000 claims 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 6
- 239000003288 aldose reductase inhibitor Substances 0.000 claims 6
- 229940090865 aldose reductase inhibitors used in diabetes Drugs 0.000 claims 6
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 5
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 5
- 230000009916 joint effect Effects 0.000 claims 5
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 claims 5
- 239000000843 powder Substances 0.000 claims 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 claims 3
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 claims 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 3
- 238000001816 cooling Methods 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 201000005577 familial hyperlipidemia Diseases 0.000 claims 3
- 238000010438 heat treatment Methods 0.000 claims 3
- 238000010992 reflux Methods 0.000 claims 3
- 230000002195 synergetic effect Effects 0.000 claims 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 2
- 102000016912 Aldehyde Reductase Human genes 0.000 claims 2
- 108010053754 Aldehyde reductase Proteins 0.000 claims 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 2
- 102000023984 PPAR alpha Human genes 0.000 claims 2
- 102000000536 PPAR gamma Human genes 0.000 claims 2
- 108010016731 PPAR gamma Proteins 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 claims 1
- FKRZCZBWVCZZLM-IBGZPJMESA-N C1=CC=CC=2OC3=CC=CC=C3N(C12)CCOC1=CC=C(C=C1)C[C@H](C)OCC Chemical compound C1=CC=CC=2OC3=CC=CC=C3N(C12)CCOC1=CC=C(C=C1)C[C@H](C)OCC FKRZCZBWVCZZLM-IBGZPJMESA-N 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 102000004316 Oxidoreductases Human genes 0.000 claims 1
- 108090000854 Oxidoreductases Proteins 0.000 claims 1
- 108091007187 Reductases Proteins 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 238000005520 cutting process Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000001704 evaporation Methods 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 230000007246 mechanism Effects 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 230000001991 pathophysiological effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
- 0 *C(CCCC(C(N)=N)=*)C(O)=O Chemical compound *C(CCCC(C(N)=N)=*)C(O)=O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/38—[b, e]-condensed with two six-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IBPCT/IB99/00681 | 1999-04-16 | ||
| PCT/IB1999/000681 WO2000063191A1 (en) | 1999-04-16 | 1999-04-16 | Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them |
| IN436MA1999 | 1999-04-19 | ||
| IN436/MAS/99 | 1999-04-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2001130883A true RU2001130883A (ru) | 2004-03-20 |
Family
ID=26318745
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2001130883/04A RU2001130883A (ru) | 1999-04-16 | 2000-04-17 | Новые полиморфные формы антидиабетического средства, способ их получения и содержащие их фармацевтические композиции |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1171430A1 (cs) |
| CN (1) | CN1351597A (cs) |
| AU (1) | AU3831300A (cs) |
| BG (1) | BG106022A (cs) |
| BR (1) | BR0010683A (cs) |
| CA (1) | CA2370401A1 (cs) |
| CZ (1) | CZ20013711A3 (cs) |
| EE (1) | EE200100529A (cs) |
| HR (1) | HRP20010748A2 (cs) |
| HU (1) | HUP0200758A3 (cs) |
| IL (1) | IL145958A0 (cs) |
| MX (1) | MXPA01010472A (cs) |
| NO (1) | NO20015016L (cs) |
| PL (1) | PL351492A1 (cs) |
| RU (1) | RU2001130883A (cs) |
| TR (1) | TR200103851T2 (cs) |
| WO (1) | WO2000063192A1 (cs) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003525908A (ja) | 2000-03-08 | 2003-09-02 | ノボ ノルディスク アクティーゼルスカブ | 血清脂質の低下 |
| US6897199B2 (en) * | 2001-02-05 | 2005-05-24 | Dr. Reddy's Laboratories Ltd. | Pharmaceutically acceptable salts of phenoxazine and phenothiazine compounds |
| JP4563675B2 (ja) | 2001-10-12 | 2010-10-13 | ハイ・ポイント・ファーマスーティカルズ、エルエルシー | 置換ピペリジン類、およびヒスタミンｈ３受容体関連疾患の治療のためのその使用 |
| CZ2004747A3 (cs) | 2001-12-21 | 2004-11-10 | Novo Nordisk A/S | Deriváty amidů jako GK aktivátory |
| MXPA04010313A (es) * | 2002-04-19 | 2005-06-08 | Faes Farma Sa | Polimorfo del acido 4- [2-[4 -[1(2- etoxietil) -1h- bencimidazol -2-il]-1 -piperidinil] etil]- alfa, alfa- dimetil -bencenoacetico. |
| WO2004002481A1 (en) | 2002-06-27 | 2004-01-08 | Novo Nordisk A/S | Aryl carbonyl derivatives as therapeutic agents |
| EP1625112B1 (en) | 2003-05-14 | 2009-07-22 | High Point Pharmaceuticals, LLC | Novel compounds for treatment of obesity |
| CA2539596A1 (en) | 2003-09-30 | 2005-04-07 | Kilian Waldemar Conde-Frieboes | Melanocortin receptor agonists |
| WO2005056036A2 (en) | 2003-12-09 | 2005-06-23 | Novo Nordisk A/S | Regulation of food preference using glp-1 agonists |
| PT1723128E (pt) | 2004-01-06 | 2013-02-27 | Novo Nordisk As | Heteroaril-ureias e o seu uso como activadores da glicoquinase |
| WO2005105785A2 (en) | 2004-05-04 | 2005-11-10 | Novo Nordisk A/S | Indole derivatives for treatment of obesity |
| WO2005120492A1 (en) | 2004-06-11 | 2005-12-22 | Novo Nordisk A/S | Counteracting drug-induced obesity using glp-1 agonists |
| WO2006053906A1 (en) | 2004-11-22 | 2006-05-26 | Novo Nordisk A/S | Soluble, stable insulin-containing formulations with a protamine salt |
| EP1824835A1 (en) | 2004-12-03 | 2007-08-29 | Novo Nordisk A/S | Heteroaromatic glucokinase activators |
| MX2007015675A (es) | 2005-07-04 | 2008-02-20 | Novo Nordisk As | Antagonistas del receptor de histamina h3. |
| WO2007006814A1 (en) | 2005-07-14 | 2007-01-18 | Novo Nordisk A/S | Urea glucokinase activators |
| EP1910317B1 (en) | 2005-07-20 | 2013-07-03 | Eli Lilly And Company | 1-amino linked compounds |
| WO2007123581A1 (en) | 2005-11-17 | 2007-11-01 | Eli Lilly And Company | Glucagon receptor antagonists, preparation and therapeutic uses |
| US8394842B2 (en) | 2006-03-28 | 2013-03-12 | High Point Pharmaceuticals, Llc | Benzothiazoles having histamine H3 receptor activity |
| BRPI0711370A2 (pt) | 2006-05-29 | 2011-11-01 | High Point Pharmaceuticals Llc | 3-(1,3-benzodioxol-5-il)-6-(4-ciclopropilpiperazin-1-il)pi ridazina e seus sais e solvatos e seu uso como antagonista receptor h3 de histamina |
| EP2097388B1 (en) | 2006-11-15 | 2011-09-07 | High Point Pharmaceuticals, LLC | Novel 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes |
| ATE538109T1 (de) | 2006-11-15 | 2012-01-15 | High Point Pharmaceuticals Llc | Neue für die behandlung von obesitas und diabetes geeignete 2-(2-hydroxyphenyl)benzothiadiazine |
| EP2099777B1 (en) | 2007-01-11 | 2015-08-12 | Novo Nordisk A/S | Urea glucokinase activators |
| JP2010013472A (ja) * | 2009-09-09 | 2010-01-21 | Faes Farma Sa | ４−［２−［１−（２−エトキシエチル）−１Ｈ−ベンズイミダゾール−２−イル］−１−ピペリジニル］エチル］−α，α−ジメチルベンゼノ酢酸の多形体 |
| WO2011104378A1 (en) | 2010-02-26 | 2011-09-01 | Novo Nordisk A/S | Peptides for treatment of obesity |
| BR112012021231A2 (pt) | 2010-02-26 | 2015-09-08 | Basf Plant Science Co Gmbh | método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto |
| CN102918056B (zh) | 2010-03-26 | 2016-08-10 | 诺沃—诺迪斯克有限公司 | 新的胰高血糖素类似物 |
| US10130684B2 (en) | 2011-02-03 | 2018-11-20 | Pharmedica Ltd. | Oral dissolving films for insulin administration, for treating diabetes |
| KR20140020292A (ko) | 2011-03-28 | 2014-02-18 | 노보 노르디스크 에이/에스 | 신규 글루카곤 유사체 |
| US8541368B2 (en) | 2011-09-23 | 2013-09-24 | Novo Nordisk A/S | Glucagon analogues |
| US20150004144A1 (en) | 2011-12-02 | 2015-01-01 | The General Hospital Corporation | Differentiation into brown adipocytes |
| RS59124B1 (sr) | 2013-04-18 | 2019-09-30 | Novo Nordisk As | Stabilni, produženi koagonisti glp-1/glukagonskih receptora za medicinsku upotrebu |
| EP3151852A1 (en) | 2014-06-04 | 2017-04-12 | Novo Nordisk A/S | Glp-1/glucagon receptor co-agonists for medical use |
| EP3596107A1 (en) | 2017-03-15 | 2020-01-22 | Novo Nordisk A/S | Bicyclic compounds capable of binding to melanocortin 4 receptor |
| WO2019219714A1 (en) | 2018-05-15 | 2019-11-21 | Novo Nordisk A/S | Compounds capable of binding to melanocortin 4 receptor |
| WO2020053414A1 (en) | 2018-09-14 | 2020-03-19 | Novo Nordisk A/S | Bicyclic compounds capable of acting as melanocortin 4 receptor agonists |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5089514A (en) * | 1990-06-14 | 1992-02-18 | Pfizer Inc. | 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents |
| US5248699A (en) * | 1992-08-13 | 1993-09-28 | Pfizer Inc. | Sertraline polymorph |
| IN182496B (cs) * | 1996-02-20 | 1999-04-17 | Reddy Research Foundation | |
| WO1997027191A1 (en) * | 1996-06-19 | 1997-07-31 | Dr. Reddy's Research Foundation | Novel polymorphic forms of troglitazone having enhanced anti-diabetic activity and a process for their preparation |
| GB9604242D0 (en) * | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
| FR2746099B1 (fr) * | 1996-03-13 | 1998-04-30 | Procede ameliore pour la preparation de derives de l'acide 3-(10-phenothiazyl)-propanoique ou 3-(10-phenoxazyl)-propanoique | |
| WO1999019313A1 (en) * | 1997-10-27 | 1999-04-22 | Dr. Reddy's Research Foundation | Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them |
| JP2002501909A (ja) * | 1998-01-29 | 2002-01-22 | ドクター・レディーズ・リサーチ・ファウンデーション | 新規なアルカン酸およびその医薬における使用、並びにその製造方法、およびそれを含有する薬学的組成物 |
| JP2002507543A (ja) * | 1998-05-27 | 2002-03-12 | ドクター・レディーズ・リサーチ・ファウンデーション | 二環系化合物、その製造方法およびそれらを含有する薬学的組成物 |
-
2000
- 2000-04-17 RU RU2001130883/04A patent/RU2001130883A/ru unknown
- 2000-04-17 MX MXPA01010472A patent/MXPA01010472A/es unknown
- 2000-04-17 HU HU0200758A patent/HUP0200758A3/hu unknown
- 2000-04-17 CZ CZ20013711A patent/CZ20013711A3/cs unknown
- 2000-04-17 WO PCT/IB2000/000470 patent/WO2000063192A1/en active Search and Examination
- 2000-04-17 CN CN00807705A patent/CN1351597A/zh active Pending
- 2000-04-17 TR TR2001/03851T patent/TR200103851T2/xx unknown
- 2000-04-17 CA CA002370401A patent/CA2370401A1/en not_active Abandoned
- 2000-04-17 HR HR20010748A patent/HRP20010748A2/hr not_active Application Discontinuation
- 2000-04-17 AU AU38313/00A patent/AU3831300A/en not_active Abandoned
- 2000-04-17 IL IL14595800A patent/IL145958A0/xx unknown
- 2000-04-17 EP EP00917222A patent/EP1171430A1/en not_active Withdrawn
- 2000-04-17 EE EEP200100529A patent/EE200100529A/xx unknown
- 2000-04-17 BR BR0010683-6A patent/BR0010683A/pt not_active IP Right Cessation
- 2000-04-17 PL PL00351492A patent/PL351492A1/xx not_active Application Discontinuation
-
2001
- 2001-10-15 NO NO20015016A patent/NO20015016L/no not_active Application Discontinuation
- 2001-10-16 BG BG106022A patent/BG106022A/bg unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0200758A2 (hu) | 2002-07-29 |
| BR0010683A (pt) | 2003-07-01 |
| TR200103851T2 (tr) | 2002-04-22 |
| CZ20013711A3 (cs) | 2002-07-17 |
| EP1171430A1 (en) | 2002-01-16 |
| MXPA01010472A (es) | 2002-05-06 |
| NO20015016L (no) | 2001-12-11 |
| IL145958A0 (en) | 2002-07-25 |
| HRP20010748A2 (en) | 2003-02-28 |
| PL351492A1 (en) | 2003-04-22 |
| EE200100529A (et) | 2002-12-16 |
| NO20015016D0 (no) | 2001-10-15 |
| AU3831300A (en) | 2000-11-02 |
| CN1351597A (zh) | 2002-05-29 |
| HUP0200758A3 (en) | 2003-07-28 |
| CA2370401A1 (en) | 2000-10-26 |
| BG106022A (bg) | 2002-04-30 |
| WO2000063192A1 (en) | 2000-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2001130883A (ru) | Новые полиморфные формы антидиабетического средства, способ их получения и содержащие их фармацевтические композиции | |
| AU749505B2 (en) | Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them | |
| JP2003508348A (ja) | 新規多型形態の抗糖尿病薬剤：それらの製造方法およびそれらを含有する医薬組成物 | |
| EP3004053B1 (en) | A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities | |
| CA2426117A1 (en) | Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation | |
| JP2004509961A5 (cs) | ||
| WO2002028857A1 (en) | Polymorphs of pioglitazone hydrochloride and their use as antidiabetics | |
| SK2632003A3 (en) | The hydrochloride salt of 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione | |
| CA2479274C (en) | Thiazolidinedione derivatives and pharmaceutical composition comprising the same | |
| JP2005523300A5 (cs) | ||
| US20040068116A1 (en) | Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino[ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation | |
| JP4634716B2 (ja) | ５−［４−［［３−メチル−４−オキソ−３，４−ジヒドロキナゾリン−２−イル］メトキシ］ベンジル］チアゾリジン−２，４−ジオンカリウム塩の新規な結晶形 | |
| WO2006042245A1 (en) | Novel isoxazole compounds having ppar agonist activity | |
| CN117043160B (zh) | Fxr受体激动剂的晶型 | |
| AU2001291232B2 (en) | Novel polymorphic forms of 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation | |
| RU2003112226A (ru) | Новые полиморфоные форы 5-[4-2-[n-метил-n-(2-пиридил)амино]этокси]тиазолидин-2,4-дион малеата и способ их получения | |
| WO2003066612A1 (en) | Novel polymorphic forms of bicyclic antidiabetic agents: process for their preparation and pharmaceutical compositions containing them | |
| CN1458930A (zh) | 噻唑烷二酮衍生物的酒石酸盐 | |
| US6528507B1 (en) | Polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them | |
| CN1620453A (zh) | 噻唑烷二酮衍生物及其作为抗糖尿病药的用途 | |
| SK3782003A3 (en) | Sodium salts of 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione | |
| AU2001291232A1 (en) | Novel polymorphic forms of 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation |